Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
Search results
548 results
-
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)
In development [GID-TA10435] Expected publication date: TBC
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
In development [GID-TA10272] Expected publication date: 14 July 2021
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
In development [GID-TA10490] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
In development [GID-TA10492] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 19 May 2021
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 19 May 2021
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]
In development [GID-TA10406] Expected publication date: 25 August 2021
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: 31 March 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]
In development [GID-TA10756] Expected publication date: 22 September 2021
-
Workplace health for employees with disabilities and long-term conditions
In development [GID-PHG58] Expected publication date: TBC
-
Workplace health - older employees
In development [GID-PHG59] Expected publication date: 24 March 2016
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
In development [GID-PHG0] Expected publication date: TBC
-
Housing: planning to improve health and wellbeing
In development [GID-NG10053] Expected publication date: TBC
-
Assessment, referral and management of Adrenal dysfunction
In development [GID-NG10052] Expected publication date: TBC
-
Diagnostic services
In development [GID-CGWAVE0773] Expected publication date: TBC
-
Reducing the mortality and morbidity for healthcare associated infections
In development [GID-NG10059] Expected publication date: TBC
-
Hernia
In development [GID-CGWAVE0771] Expected publication date: TBC
-
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
In development [GID-TA10474] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]
In development [GID-TA10595] Expected publication date: TBC
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Galcanezumab for preventing cluster headache [ID1212]
In development [GID-TA10425] Expected publication date: 24 February 2021
-
Blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia [ID1008]
In development [GID-TA10119] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC